vs
LXP Industrial Trust（LXP）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
LXP Industrial Trust的季度营收约是MESA LABORATORIES INC的1.3倍（$86.7M vs $65.1M），LXP Industrial Trust净利率更高（33.2% vs 5.6%，领先27.6%），MESA LABORATORIES INC同比增速更快（3.6% vs -14.0%），过去两年MESA LABORATORIES INC的营收复合增速更高（5.1% vs 0.3%）
LXP工业信托是一家公开上市的房地产投资信托，专注于持有、运营和投资美国核心市场的优质工业地产，主要涵盖配送中心、物流设施及轻型工业物业，服务电商、第三方物流、先进制造等领域租户，为投资者创造长期稳定收益。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
LXP vs MLAB — 直观对比
营收规模更大
LXP
是对方的1.3倍
$65.1M
营收增速更快
MLAB
高出17.6%
-14.0%
净利率更高
LXP
高出27.6%
5.6%
两年增速更快
MLAB
近两年复合增速
0.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $86.7M | $65.1M |
| 净利润 | $28.8M | $3.6M |
| 毛利率 | 81.5% | 64.2% |
| 营业利润率 | 34.6% | 12.2% |
| 净利率 | 33.2% | 5.6% |
| 营收同比 | -14.0% | 3.6% |
| 净利润同比 | — | 316.6% |
| 每股收益（稀释后） | — | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LXPMLAB
| Q4 25 | $86.7M | $65.1M | ||
| Q3 25 | $86.9M | $60.7M | ||
| Q2 25 | $87.7M | $59.5M | ||
| Q1 25 | $88.9M | $62.1M | ||
| Q4 24 | $100.9M | $62.8M | ||
| Q3 24 | $85.6M | $57.8M | ||
| Q2 24 | $85.8M | $58.2M | ||
| Q1 24 | $86.3M | $58.9M |
净利润LXPMLAB
| Q4 25 | $28.8M | $3.6M | ||
| Q3 25 | $36.3M | $2.5M | ||
| Q2 25 | $29.1M | $4.7M | ||
| Q1 25 | $19.0M | $-7.1M | ||
| Q4 24 | — | $-1.7M | ||
| Q3 24 | $6.3M | $3.4M | ||
| Q2 24 | $5.4M | $3.4M | ||
| Q1 24 | $-269.0K | $-254.6M |
毛利率LXPMLAB
| Q4 25 | 81.5% | 64.2% | ||
| Q3 25 | 82.3% | 61.5% | ||
| Q2 25 | 81.9% | 62.0% | ||
| Q1 25 | 80.7% | 61.8% | ||
| Q4 24 | 85.3% | 63.3% | ||
| Q3 24 | 82.5% | 61.3% | ||
| Q2 24 | 82.0% | 64.0% | ||
| Q1 24 | 82.4% | 62.1% |
营业利润率LXPMLAB
| Q4 25 | 34.6% | 12.2% | ||
| Q3 25 | 50.4% | 7.8% | ||
| Q2 25 | 33.7% | 5.1% | ||
| Q1 25 | 21.8% | 2.4% | ||
| Q4 24 | — | 9.2% | ||
| Q3 24 | 7.9% | 6.1% | ||
| Q2 24 | 6.9% | 9.6% | ||
| Q1 24 | 1.0% | -460.6% |
净利率LXPMLAB
| Q4 25 | 33.2% | 5.6% | ||
| Q3 25 | 41.7% | 4.1% | ||
| Q2 25 | 33.2% | 8.0% | ||
| Q1 25 | 21.4% | -11.4% | ||
| Q4 24 | — | -2.7% | ||
| Q3 24 | 7.4% | 5.9% | ||
| Q2 24 | 6.3% | 5.8% | ||
| Q1 24 | -0.3% | -432.2% |
每股收益（稀释后）LXPMLAB
| Q4 25 | — | $0.65 | ||
| Q3 25 | $0.12 | $0.45 | ||
| Q2 25 | $0.09 | $0.85 | ||
| Q1 25 | $0.06 | $-1.30 | ||
| Q4 24 | — | $-0.31 | ||
| Q3 24 | $0.02 | $0.63 | ||
| Q2 24 | $0.01 | $0.62 | ||
| Q1 24 | $-0.01 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $170.4M | $29.0M |
| 总债务越低越好 | $1.4B | $68.4M |
| 股东权益账面价值 | $2.0B | $186.7M |
| 总资产 | $3.5B | $434.8M |
| 负债/权益比越低杠杆越低 | 0.66× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资LXPMLAB
| Q4 25 | $170.4M | $29.0M | ||
| Q3 25 | $229.7M | $20.4M | ||
| Q2 25 | $71.0M | $21.3M | ||
| Q1 25 | $70.9M | $27.3M | ||
| Q4 24 | $101.8M | $27.3M | ||
| Q3 24 | $55.0M | $24.3M | ||
| Q2 24 | $48.7M | $28.5M | ||
| Q1 24 | $293.8M | $28.2M |
总债务LXPMLAB
| Q4 25 | $1.4B | $68.4M | ||
| Q3 25 | $1.5B | $69.4M | ||
| Q2 25 | $1.5B | $70.3M | ||
| Q1 25 | $1.5B | $71.3M | ||
| Q4 24 | $1.6B | $72.2M | ||
| Q3 24 | — | $73.1M | ||
| Q2 24 | — | $74.1M | ||
| Q1 24 | — | — |
股东权益LXPMLAB
| Q4 25 | $2.0B | $186.7M | ||
| Q3 25 | $2.1B | $178.5M | ||
| Q2 25 | $2.1B | $172.5M | ||
| Q1 25 | $2.1B | $159.8M | ||
| Q4 24 | $2.1B | $155.2M | ||
| Q3 24 | $2.1B | $161.5M | ||
| Q2 24 | $2.1B | $150.7M | ||
| Q1 24 | $2.2B | $145.4M |
总资产LXPMLAB
| Q4 25 | $3.5B | $434.8M | ||
| Q3 25 | $3.7B | $430.4M | ||
| Q2 25 | $3.7B | $435.7M | ||
| Q1 25 | $3.8B | $433.3M | ||
| Q4 24 | $3.8B | $433.3M | ||
| Q3 24 | $3.9B | $454.1M | ||
| Q2 24 | $3.9B | $440.4M | ||
| Q1 24 | $4.2B | $446.8M |
负债/权益比LXPMLAB
| Q4 25 | 0.66× | 0.37× | ||
| Q3 25 | 0.72× | 0.39× | ||
| Q2 25 | 0.72× | 0.41× | ||
| Q1 25 | 0.73× | 0.45× | ||
| Q4 24 | 0.75× | 0.47× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.49× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $188.7M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | 6.56× | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流LXPMLAB
| Q4 25 | $188.7M | $18.8M | ||
| Q3 25 | $63.5M | $8.2M | ||
| Q2 25 | $44.3M | $1.9M | ||
| Q1 25 | $39.0M | $12.7M | ||
| Q4 24 | $211.2M | $18.1M | ||
| Q3 24 | $64.6M | $5.3M | ||
| Q2 24 | $38.5M | $10.7M | ||
| Q1 24 | $38.9M | $12.9M |
自由现金流LXPMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率LXPMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度LXPMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率LXPMLAB
| Q4 25 | 6.56× | 5.17× | ||
| Q3 25 | 1.75× | 3.32× | ||
| Q2 25 | 1.52× | 0.40× | ||
| Q1 25 | 2.05× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.18× | 1.54× | ||
| Q2 24 | 7.09× | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LXP
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
